“
“There is an intimate association between mineral and bone disorders in chronic kidney disease (CKD) and the extensive burden of cardiovascular disease (CVD) in this population. High phosphate levels in CKD have been associated with increased all-cause mortality and cardiovascular morbidity and mortality. Observational studies have also shown a consistent relationship between serum phosphate in the normal range and all-cause and cardiovascular mortality, left ventricular hypertrophy (LVH) and decline in renal

function. Furthermore, fibroblast growth factor-23 (FGF-23), a phosphaturic hormone, increases very early in the course of CKD and is strongly associated with death and CVD, including LVH and vascular calcification. Few studies have addressed outcomes AZD1208 order using interventions to reduce serum phosphate in a randomized controlled fashion; however, strategies to address cardiovascular risk in early CKD are imperative and phosphate is a potential therapeutic target. This HM781-36B review outlines the epidemiological and experimental evidence highlighting the relationship between excess phosphate and adverse outcomes, and discusses clinical

studies required to address this problem. High serum phosphate is a major risk factor for death, cardiovascular disease (CVD) and vascular calcification among patients with and without chronic kidney disease (CKD).1–5 Even serum phosphate levels within the normal range are associated with increased mortality, CVD and renal disease progression.1–3,6 Mechanisms by which increased phosphate leads to adverse outcomes are not fully understood, but evidence suggests a direct effect of phosphate on vascular calcification and endothelial dysfunction as well as modulation of key hormones Loperamide such as fibroblast growth factor-23 (FGF-23). There is increasing

observational data linking phosphate excess and high FGF-23 with CVD and mortality, and therapies that effectively reduce serum phosphate concentration are of tremendous contemporary interest as putative therapeutic agents to reduce the CVD burden in CKD. However, no clinical trials have been conducted to establish a causal relationship between phosphate and adverse outcomes. Patients with CKD have a disruption in systemic calcium and phosphate homeostasis. As a result of renal damage, progressively higher levels of FGF-23 (released from bone) are required to increase phosphate excretion from residual nephrons. Together with diminished conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (1,25(OH)2D), these changes affect bone turnover, gastrointestinal absorption of calcium and phosphate, and parathyroid function, with consequences for bone integrity and mineral metabolism.